h-header

news

News dal mondo

22

Lug

India reports steep rise in API prices

India, which is just about emerging out of a deadly second wave of Covid-19, is now battling with a steep rise in the cost of active pharmaceutical ingredients (API). In certain cases, the price rise is as high as 139 percent since the pre-pandemic levels, says a report published in The Economic Times.

Nearly 70 percent of India’s APIs are imported from China, and the dependence is as high as 90 percent for antibiotics like cephalosporinsazithromycin and penicillin.“The overall increase, averaging nearly 50 percent in the wake of high-priced imports and supply disruptions from China, have raised doubts on the availability of drugs and could lead to shortages, particularly of those that are key in Covid therapy,” says the ET report.

This rise in API prices is hurting the industry. The prices of drugs such as paracetamolmeropenem and metformin, have increased 139 percent, 127 percent and 124 percent respectively. In India, these drugs are under price control, compelling companies to absorb the higher costs. Moreover, packaging and freight costs have also jumped manifold, ranging from 100 percent for packaging materials, and between 233 percent and 360 percent for shipping freight rates from China. [PharmaCompass]

17

Set

Governo vara decreto legge su green pass obbligatorio nel luoghi di lavoro pubblici e privati

Dal 15 ottobre e fino al 31 dicembre 2021, termine di cessazione dello stato di emergenza, la Certificazione...

15

Set

Publication of a new general chapter on balances in European Pharmacopoeia Supplement 10.6

At its 168th session (November 2020), the European Pharmacopoeia (Ph. Eur.) Commission adopted...

15

Set

EU - Strategia in materia di sostanze chimiche per la sostenibilità

Risoluzione del Parlamento europeo del 10 luglio 2020 sulla strategia in materia di sostanze chimiche...

10

Set

FDA . Development of Abbreviated New Drug Applications During the COVID-19 Pandemic – Questions and Answers

US FDA's updated Q&A guidance on developing generics for submission via the abbreviated new...

slider-banner

h-footer